Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant cisplatin-based doublet chemotherapy in Masaoka stage III–IV thymic epithelial tumors
ChiCTR2400084477Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in thymic malignancies (TET), sponsored by Shanghai General Hospital. Primary endpoint: Pathological complete response. Planned start May 2024; status: not yet recruiting.
02
Drugs
cisplatin
03
Conditions
thymic malignancies (TET)
Beyond the preview
Go deeper on ChiCTR2400084477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084477.